MedPath

The Role of Probiotics PS128 in Movement Disorders

Not Applicable
Conditions
Rett Syndrome
Tourette Syndrome
Tic Disorders
Interventions
Dietary Supplement: Placebo
Dietary Supplement: Probiotic-Lactobacillus plantarum PS128
Registration Number
NCT03259971
Lead Sponsor
National Taiwan University Hospital
Brief Summary

Pediatric movement disorders comprise of a large number of different neurological diseases including Rett syndrome (RTT) and Tourette syndrome. Studies in the literature as well as our preliminary reports showed that Rett syndrome and Tourette syndrome/Tic disorders are associated with a dysbiosis of the gut microbiota compared to normal control. Probiotic Lactobacillus plantarum PS128 is a diet supplement that available for human consumption. Probiotic Lactobacillus plantarum PS128 had showed psychotropic effects such as ameliorate anxiety- and depression-like behaviors as well as altered the level of neurotransmitters such as dopamine in the brain in animal models, which might be through microbiota-gut-brain axis. Therefore, the purpose of this study is to access the possible neurobehavior effects of Probiotic Lactobacillus plantarum PS128 in Rett syndrome and Tic disorders/Tourette syndrome.

Detailed Description

The study is a placebo-controlled double-blind randomized study, to determine the benefits of probiotic Lactobacillus plantarum PS128 vs placebo on symptoms for Tic disorders; and the symptoms, behavior, or cognition for Rett syndrome.

Patients with the Rett syndrome and Tic disorders/Tourette syndrome will be recruited into our study.The study period will last 4 months for Rett syndrome patients, age one year-50years; while 2 months for Tic disorders/Tourette syndrome patient, age 5 years-18 years.

The study will be performed in National Taiwan University Children Hospital. The patients will have neuropsychological and gut microbiota evaluation before and at the end of the study. There will also be interim follow up evaluations each month after the patient start taking the probiotic or placebo.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
500
Inclusion Criteria
  • Rett syndrome:
  • Males and females who have classic or atypical RTT diagnosed under consensus criteria
  • Age: 1-50 years
  • Tic disorders:
  • males and females with clinical diagnosis
  • Age: 8-18years
  • Treatment naive 4 weeks prior to study
  • Those with standard medications, dosage stable 4 weeks prior to study
  • AADC syndrome:
  • Males and females with AADC diagnosis
  • Age: 1-50 years
Exclusion Criteria
  • Those who took probiotic or probiotic related product 4 weeks prior to the study or during the study
  • Those who took antibiotic 4 weeks prior to the study
  • Those showing poor compliance with any aspect of the study
  • Those had adverse reactions to PS128

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Placebo (for tic disorder)PlaceboThe placebo will be dispensed to equal the volume of 1 tablet of Probiotic PS128, which is taken orally in 2 divided doses, 12 hours apart during the study period of 2 months for Tic disorders.
Placebo (for Rett syndrome)PlaceboThe placebo will be dispensed to equal the volume of 1 tablet of Probiotic PS128, which is taken orally in 2 divided doses, 12 hours apart during the study period of 4 months for Rett syndrome
PS128 (Rett syndrome)Probiotic-Lactobacillus plantarum PS128The Probiotic group will take Probiotic-Lactobacillus plantarum PS128, which contain 300mg (3x10\^10 CFU) Lactobacillus plantarum PS128 and 100mg of Microcrystalline Cellulose in each tablet. It will be taken orally in 2 divided doses, 12 hours apart during the study period of 4 months for Rett Syndrome.
PS128 (tic disorder)Probiotic-Lactobacillus plantarum PS128The Probiotic group in tic disorder will take Probiotic-Lactobacillus plantarum PS128, which contain 300mg (3x10\^10 CFU) Lactobacillus plantarum PS128 and 100mg of Microcrystalline Cellulose in each tablet. It will be taken orally in 2 divided doses, 12 hours apart during the study period of 2 months for Tic disorders.
Primary Outcome Measures
NameTimeMethod
Neuropsychological test (Mullen Scales of Early Learning)Change at four months from baseline

for Rett syndrome

Yale Global Tic Severity Scale (YGTSS)Change at 2 months from baseline

for Tic disorders

Secondary Outcome Measures
NameTimeMethod
Children's Depression InventoryChange at 2 months from baseline

For Tic disorders

RTT severity scoreChange at four months from baseline

For Rett syndrome

Anxiety, Depression, and Mood Scale (ADAMS)Change at four months from baseline

For Rett syndrome

Early social communication scalesChange at four months from baseline

For Rett syndrome

The Migraine Disability Assessment TestChange at 2 months from baseline

For Tic disorders

Dystonia status (Fahn Marsden rating scale/Unified Dystonia Rating Scale )Visit 1, Visit 2, Visit 3, Visit 4 (Up to 4 months)

For Rett syndrome

Vineland Adaptive Behavioral scaleChange at four months from baseline

For Rett syndrome

Pediatric Evaluation of Disability InventoryChange at four months from baseline

For Rett syndrome

Stool and gut microbiota evaluationChange at four months from baseline

For Rett and Tic disorders

Child Behavior Checklist (CBCL)Change at 2 months from baseline

For Tic disorders

Continuous performance testChange at 2 months from baseline

For Tic disorders

Obsessive-compulsive inventoryChange at 2 months from baseline

For Tic disorders

Ghuman-Folstein Screen for Social Interaction (SSI)Change at four months from baseline

For Rett syndrome

Swanson, Nolan and Pehlam version IVChange at 2 months from baseline

For Tic disorders

Trial Locations

Locations (1)

National Taiwan University Children Hospital

🇨🇳

Taipei, Taiwan

© Copyright 2025. All Rights Reserved by MedPath